Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1865-8652

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study ; volume:37 ; number:9 ; day:9 ; month:7 ; year:2020 ; pages:3775-3790 ; date:9.2020
Advances in therapy ; 37, Heft 9 (9.7.2020), 3775-3790, 9.2020

Creator: Tabberer, Maggie
Jones, C. Elaine
Kilbride, Sally
Halpin, David M. G.
Lomas, David A.
Pascoe, Steven
Singh, Dave
Wise, Robert A.
Criner, Gerard J.
Lange, Peter
Dransfield, Mark T.
Han, MeiLan K.
Martinez, Fernando J.
Kaisermann, Morrys C.
Lipson, David A.

Contributor: SpringerLink (Online service)

DOI: 10.1007/s12325-020-01409-8

URN: urn:nbn:de:101:1-2020100703321047653161

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:03 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Tabberer, Maggie
Jones, C. Elaine
Kilbride, Sally
Halpin, David M. G.
Lomas, David A.
Pascoe, Steven
Singh, Dave
Wise, Robert A.
Criner, Gerard J.
Lange, Peter
Dransfield, Mark T.
Han, MeiLan K.
Martinez, Fernando J.
Kaisermann, Morrys C.
Lipson, David A.
SpringerLink (Online service)

Other Objects (12)

Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials

Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma

Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review

Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials

Inhalationstherapie mit dem Respimat® Soft Inhaler bei Asthma und COPD

Inhaler devices in asthma and COPD patients : a prospective cross-sectional study on inhaler preferences and error rates

Inhaler devices in asthma and COPD patients – a prospective cross-sectional study on inhaler preferences and error rates

Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial

Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study

Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials

Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma

Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review

Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials

Inhalationstherapie mit dem Respimat® Soft Inhaler bei Asthma und COPD

Inhaler devices in asthma and COPD patients : a prospective cross-sectional study on inhaler preferences and error rates

Inhaler devices in asthma and COPD patients – a prospective cross-sectional study on inhaler preferences and error rates

Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial

Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study

Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials

Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma

Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review

Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials

Inhalationstherapie mit dem Respimat® Soft Inhaler bei Asthma und COPD

Inhaler devices in asthma and COPD patients : a prospective cross-sectional study on inhaler preferences and error rates

Inhaler devices in asthma and COPD patients – a prospective cross-sectional study on inhaler preferences and error rates

Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial

Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials

Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma

Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review

Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials

Inhalationstherapie mit dem Respimat® Soft Inhaler bei Asthma und COPD

Inhaler devices in asthma and COPD patients : a prospective cross-sectional study on inhaler preferences and error rates

Inhaler devices in asthma and COPD patients – a prospective cross-sectional study on inhaler preferences and error rates

Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial

Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study

Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials

Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma

Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review

Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials

Inhalationstherapie mit dem Respimat® Soft Inhaler bei Asthma und COPD

Inhaler devices in asthma and COPD patients : a prospective cross-sectional study on inhaler preferences and error rates

Inhaler devices in asthma and COPD patients – a prospective cross-sectional study on inhaler preferences and error rates

Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial

Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study

Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials

Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma

Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review

Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials

Inhalationstherapie mit dem Respimat® Soft Inhaler bei Asthma und COPD

Inhaler devices in asthma and COPD patients : a prospective cross-sectional study on inhaler preferences and error rates

Inhaler devices in asthma and COPD patients – a prospective cross-sectional study on inhaler preferences and error rates

Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial

Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study

Related objects

Reset password